Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Navamedic M&A Activity 2016

Mar 3, 2016

3668_iss_2016-03-03_53416cd8-7483-4e4a-b80c-cd3d513362cc.html

M&A Activity

Open in viewer

Opens in your device viewer

Navamedic expands cooperation with Pohl-Boskamp

Navamedic expands cooperation with Pohl-Boskamp

Oslo, 3 March 2016 - Navamedic ASA (OSE: NAVA) the Norwegian medtech and

pharmaceutical marketing- and distribution company today announced an expanded

cooperation agreement with German pharmaceutical manufacturer, Pohl-Boskamp, for

distribution of Nitrolingual® Pumpspray in the Nordic markets.

Nitrolingual® Pumpspray is an oral spray of nitroglycerine used for relief or

prevention of sudden attacks of chest pain associated with angina pectoris

caused by heart disease. Annual sales of Nitrolingual® in the Nordic markets are

expected to be around NOK 8 million.

"Our cooperation with Pohl-Boskamp has proven highly successful. We are

delighted to add Nitrolingual to our portfolio and expect it to be very well-

received in the Nordic markets. The expansion is in line with the growth

strategy we are pursuing in this region, based on high-performing products and

working with strong suppliers," said Tom Rönnlund, CEO of Navamedic.

Navamedic has distributed several Pohl-Boskamp products in the Nordic markets

since 2014, including NYDA® head lice treatment and GeloRevoice® throat

lozenges, which are now available at more than 1,400 pharmacies across the

Nordic region.

"We are pleased to have a solid partner in Navamedic. We look forward to

continuing the collaboration and working together to bring new treatment

products into the Nordic markets," added Bodo Heibrock, Senior Director of

International Sales at Pohl-Boskamp.

For further information, please contact:

Tom Rönnlund, CEO Navamedic

Telephone +46 727 320 321

About Navamedic

Navamedic ASA is a Norwegian medtech and pharmaceutical products company,

delivering products to hospitals, pharmacies and health products stores in the

Nordic and Benelux markets. The Group's Medtech business has developed and is

currently introducing the next generation digital urine meter Sippi ®.

Navamedic's Pharma and Healthcare business is a distributor of products supplied

by a number of pharmaceutical manufacturers. Navamedic is listed on the Oslo

Stock Exchange (ticker: NAVA).

www.navamedic.com

About Pohl-Boskamp

Pohl-Boskamp is a privately owned business active in the international

pharmaceutical market for 175 years with commercialized products in more than

45 countries. Through close collaboration with its partners abroad, Pohl-Boskamp

focuses on developing and marketing products that positively impact patients'

quality of life. It operates in numerous healthcare sectors including

pneumology, urology, parasitology, cardiovascular diseases, gastroenterology,

sleep disorders and dermatology.

http://www.pohl-boskamp.com/en/.

[HUG#1991491]